Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in Taiwan
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Journal Volume
119
Journal Issue
5
Pages
907
Date Issued
2020-05
Author(s)
FANG-JU LIN
Shyu, Kou-Gi
Hsieh, I-Chang
Huey-Herng Sheu, Wayne
Tu, Shih-Te
Yeh, Shoou-Jeng
Chen, Chin-I
Lu, Kuo-Cheng
Wu, Chia-Chao
Shau, Wen-Yi
Inocencio, Timothy J
Wen, Yao-Chun
Yeh, Hung-I
Abstract
The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70-100 mg/dL in Taiwan could be cost-effective.
Subjects
Coronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin
SDGs
Other Subjects
atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; pitavastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; Article; cardiac patient; cerebrovascular accident; cohort analysis; coronary artery disease; cost effectiveness analysis; drug cost; drug use; gross national product; health care cost; health status; heart infarction; human; incidence; major clinical study; Markov chain; mortality rate; probability; quality adjusted life year; recurrent disease; secondary prevention; sensitivity analysis; Taiwan; coronary artery disease; cost benefit analysis; economics; epidemiology; secondary prevention; Cholesterol, LDL; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Taiwan
Publisher
ELSEVIER TAIWAN
Type
journal article